Endometrial Hyperplasia: Types, Diagnosis, and Cancer Risk

Endometrial hyperplasia is an overgrowth of the tissue lining the uterus, driven primarily by too much estrogen without enough progesterone to keep it in check. The condition ranges from a benign thickening that often reverses on its own to an atypical form that carries a meaningful risk of becoming endometrial cancer. Understanding where a particular case falls on that spectrum matters enormously, because the treatment options and urgency differ dramatically depending on whether abnormal cells are present.

What Happens Inside the Uterus

Every menstrual cycle, estrogen stimulates the uterine lining to grow, preparing it for a possible pregnancy. After ovulation, progesterone steps in and stabilizes that lining, eventually triggering it to shed if no pregnancy occurs. When estrogen keeps driving growth without progesterone’s counterbalance, the lining thickens beyond normal limits. Over time, the glands and supporting tissue in the endometrium become crowded and disorganized. In some cases, the cells themselves begin to look abnormal under a microscope, a feature pathologists call “atypia.”

The most common symptom is abnormal uterine bleeding: periods that are heavier than usual, cycles that come irregularly, or bleeding that shows up after menopause. Postmenopausal bleeding in particular is a red flag that prompts evaluation, because prolonged unopposed estrogen exposure can cause the endometrium to shed unpredictably.¹ Some people have no symptoms at all and learn about the thickening incidentally during imaging for an unrelated issue.

How It Is Classified

For years, endometrial hyperplasia was split into four categories based on how complex the glandular architecture looked and whether cells showed atypia: simple without atypia, complex without atypia, simple with atypia, and complex with atypia. In 2014, the World Health Organization simplified the system to just two groups: benign hyperplasia (previously the non-atypical forms) and atypical hyperplasia, also called endometrial intraepithelial neoplasia. The earlier four-group classification estimated that atypical hyperplasia progressed to cancer in roughly 8 to 29 percent of cases.²

The newer two-category system reflects the reality that what matters most clinically is whether or not atypia is present. The benign form overwhelmingly responds to hormonal treatment and rarely progresses. The atypical form behaves very differently, and more recent data suggests its cancer risk may be even higher than the older estimates indicated.

Who Is at Risk

Anything that exposes the uterine lining to estrogen without adequate progesterone raises the odds. The major drivers are obesity, polycystic ovarian syndrome (PCOS), metabolic dysfunction, and extended use of unopposed estrogen therapy.³ Obesity deserves special attention because fat tissue converts androgens into estrogen, creating a chronic low-grade estrogen excess that does not fluctuate the way normal ovarian cycling does. The higher your body mass index, the longer and more persistent that estrogen exposure becomes.

PCOS is another common contributor. Women with PCOS frequently do not ovulate regularly, which means progesterone levels stay low for long stretches. On top of that, PCOS often brings insulin resistance and chronic low-grade inflammation, both of which can further disrupt the endometrium.⁴

Two less intuitive risk factors are worth knowing about. Tamoxifen, a drug widely used to treat breast cancer, acts as an estrogen blocker in breast tissue but behaves like estrogen in the uterus. In a large Korean cohort study, premenopausal women with breast cancer who took tamoxifen had a significantly higher incidence of endometrial hyperplasia and other uterine pathologies compared to those who did not receive the drug.⁵ Estrogen-secreting ovarian tumors, particularly granulosa cell tumors, can also push estrogen levels high enough to cause hyperplasia. In one review, hyperplasia was documented in about 29 percent of patients with granulosa cell tumors at the time of surgery, and endometrial cancer was found in roughly 8 percent.⁶

When Hyperplasia Becomes Cancer

The distinction between benign hyperplasia and atypical hyperplasia is not just an academic one. Benign hyperplasia carries a low progression risk. Atypical hyperplasia is a different story: estimates of its risk of progressing to endometrial cancer range from about 20 to 50 percent, depending on the patient’s specific characteristics and underlying genetic mutations.⁷

Even more striking is how often cancer is already present at the time atypical hyperplasia is diagnosed on a biopsy. A Gynecologic Oncology Group study found that when women who had been diagnosed with atypical hyperplasia on biopsy then underwent hysterectomy, about 43 percent of the surgical specimens already contained endometrial carcinoma.⁸ A more recent European study reported a concurrent cancer rate of about 31 percent in the same scenario.⁹ These numbers do not mean that every biopsy-diagnosed atypical hyperplasia case was misdiagnosed; rather, the biopsy sampled one area while cancer existed elsewhere in the lining.

Several patient characteristics raise the odds of concurrent cancer. One study found that age over 60, a body mass index above 35, and having diabetes were all independent predictors of finding cancer at the time of hysterectomy in women whose biopsy had shown hyperplasia.¹⁰ For women managed conservatively without surgery, about a quarter of atypical hyperplasia cases progressed to cancer within five years.¹¹

How It Is Diagnosed

The diagnostic workup usually starts with a transvaginal ultrasound to measure endometrial thickness. For postmenopausal women with bleeding, a thin endometrium makes serious pathology unlikely, while a thick one raises suspicion. For asymptomatic postmenopausal women, one study found that a threshold of 8 millimeters had strong sensitivity for detecting cancer and atypical hyperplasia but caught a lot of normal cases too, meaning specificity was limited.¹² A systematic review looking at asymptomatic women suggested that a higher threshold around 11 to 12 millimeters might perform better for screening in that population, balancing sensitivity against the high rate of unnecessary biopsies a lower cutoff generates.¹³

Ultrasound alone cannot make the diagnosis. A tissue sample is required, and there are different ways to get one. The standard office approach is a blind endometrial biopsy using a thin suction catheter. But a systematic review and meta-analysis found that taking the biopsy under direct hysteroscopic visualization, where a camera allows the clinician to see the lining, was associated with significantly better sample quality and a lower risk of missing hyperplasia or cancer compared to the blind technique.¹⁴ In practice, a blind office biopsy is still the first step for most patients, with hysteroscopy reserved for cases where the initial sample is inconclusive or symptoms persist despite a negative biopsy.

Treating Hyperplasia Without Atypia

When the biopsy shows benign hyperplasia with no atypical cells, progestin therapy is the standard approach. The hormone counteracts the estrogen-driven growth and encourages the lining to return to normal. Two delivery methods dominate: oral progestin pills and the levonorgestrel-releasing intrauterine device (commonly known by brand names like Mirena). The IUD consistently outperforms pills.

A meta-analysis of randomized trials found that the levonorgestrel IUD achieved significantly higher regression rates at every time point measured compared to oral progestins, and the difference grew with longer follow-up. By 24 months, the IUD was roughly seven times more likely to produce a complete response.¹⁵ Another large study reported a 93 percent regression rate with the IUD versus 66 percent with oral progestins.¹⁶ Patients treated with the IUD were also significantly less likely to end up needing a hysterectomy.¹⁷

The IUD’s advantage makes sense. It delivers progestin directly to the uterine lining at high local concentrations, rather than requiring the hormone to circulate through the entire body. That means fewer systemic side effects like mood changes and bloating, which are common reasons people stop taking oral progestins.

Treating Atypical Hyperplasia

When atypia is present, the stakes are higher. The American College of Obstetricians and Gynecologists states that hysterectomy is the definitive treatment for atypical hyperplasia, and specifically advises against supracervical hysterectomy (removing only the upper part of the uterus) because it leaves behind tissue that could harbor or develop cancer.¹⁸ Laparoscopic (minimally invasive) hysterectomy is the most common surgical approach, though surgeons must take precautions against the possibility of undiagnosed concurrent cancer during the procedure, such as sealing the fallopian tubes before inserting surgical instruments to prevent potential cancer cells from spreading.¹⁹

For younger patients who want to preserve fertility, surgery is not the only path. Progestin-based fertility-sparing treatment has been studied and appears to be a viable alternative for selected cases of early-stage endometrial cancer and atypical hyperplasia.²⁰ About three-quarters of patients with atypical hyperplasia respond to progestin therapy.²¹ The trade-off is ongoing surveillance: repeat biopsies every few months to confirm the lining is normalizing, and a clear plan to proceed with hysterectomy once childbearing is complete, because recurrence rates are not trivial.

The Genetic Side of Progression

Researchers have been mapping the molecular changes that separate hyperplasia that stays put from hyperplasia that turns into cancer. Mutations in genes like PTEN, PIK3CA, and FGFR2, all of which are commonly altered in endometrial cancer, showed up more frequently in hyperplasia cases that eventually progressed. Mutations in ARID1A and MYC appeared exclusively in progressing cases, though they were uncommon enough to limit their usefulness as diagnostic red flags.²² Chromosomal deletions on the short arm of chromosome 8 have been detected in both hyperplasia and cancer samples, suggesting this may be one of the earlier genetic events on the path toward malignancy.²³

On the clinical side, tissue biomarkers are being studied to help predict who will respond to progestin therapy and who will not. Loss of a protein called PTEN appears to be one of the strongest signals. Patients whose tissue showed persistent PTEN loss on follow-up biopsies were much more likely to fail progestin treatment, while those without these abnormalities fared better. Combining PTEN assessment with two other markers, PAX2 and beta-catenin, improved the ability to identify non-responders early.²⁴ These tools are not yet standard clinical practice. A systematic review found that more research is needed to validate most proposed biomarkers for predicting treatment response.²⁵

Weight Loss and Endometrial Health

Given that obesity is one of the strongest risk factors, the question of whether weight loss can reverse hyperplasia is a natural one. A systematic review looked at outcomes after bariatric surgery in women with obesity who had endometrial hyperplasia. Of the women who had hyperplasia before surgery and underwent repeat sampling afterward, about 71 percent showed complete resolution of the abnormal tissue. A handful had partial regression or persistent disease.²⁶ Those numbers sound encouraging, but the authors were candid that the data was poor in quality and too limited to draw firm conclusions. Whether non-surgical weight loss produces similar benefits remains largely unknown.

Weight loss after bariatric surgery involves dramatic hormonal shifts beyond just reduced estrogen production. Insulin levels drop, chronic inflammation decreases, and metabolic profiles improve broadly. Teasing apart which of those changes drives the endometrial benefit, and whether a more modest weight reduction through diet and exercise would do the same thing, is something the existing research has not answered. For now, weight management is sensible general advice for reducing risk, but it should not be treated as a substitute for medical treatment in someone who already has hyperplasia.

The Emotional Toll of a Pre-Cancer Diagnosis

A diagnosis that includes words like “atypical” and “pre-cancer” understandably generates anxiety. Research on patients undergoing fertility-sparing treatment for atypical hyperplasia or early endometrial cancer found that anxiety levels decreased progressively during treatment, and that improvement appeared tied to how quickly the condition responded: earlier remission meant faster anxiety relief. Depression levels, however, remained relatively stable throughout.²⁷ The uncertainty of not knowing whether the disease will respond or progress takes a real psychological toll, particularly for younger women grappling with the possibility of losing their fertility.

In a prospective study of women undergoing fertility-sparing management, over half indicated that psychological support should be made available as part of their care.²⁸ That is a clear signal that treatment pathways for this condition ought to include more than just biopsies and hormones. Asking your care team about counseling resources or connecting with other patients going through the same process is reasonable and worth pursuing early rather than waiting until distress peaks.